TY - JOUR
AB - PharmacoEconomics & Outcomes News 594 - 9 Jan 2010 ■ Sales of drugs for atrial fibrillation are projected to grow from $790 million in 2008 to $6.1 billion by 2018, across US, Japanese and key European markets Decision Resources has found, according to PharmaTimes. This growth is expected to be driven by launches of new agents, including oral fixed-dose anticoagulants such as Pradaxa [dabigatran etexilate] and Xarelto [rivaroxaban]. During this time frame, Multaq [dronedarone] is expected to capture 11% of the total atrial fibrillation market patient share, resulting in sales of $660 million. Kynapid [vernakalant] is also expected to achieve US sales of $130 million in 2018 due to expectations that it will provide an attractive alternative to electrical cardioversion. PharmaTimes. Atrial fibrillation drug sales "to grow sevenfold-plus by 2018". Internet Document : [2 pages], 15 Dec 2009. Available from: URL: http:// www.pharmatimes.com 801052845 1173-5503/10/0594-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved PharmacoEconomics & Outcomes News 9 Jan 2010 No. 594 
TI - Atrial fibrillation drug sales projected to grow
JF - PharmacoEconomics & Outcomes News
DO - 10.2165/00151234-201005940-00034
DA - 2013-02-09
UR - https://www.deepdyve.com/lp/springer-journals/atrial-fibrillation-drug-sales-projected-to-grow-20pgxc2Xi8
SP - 11
EP - 11
VL - 594
IS - 1
DP - DeepDyve
ER -